天眼查商业履历信息显示，熵基科技股份有限公司，成立于2007年，位于东莞市，是一家以从事计算 机、通信和其他电子设备制造业为主的企业。企业注册资本23535.155万人民币，实缴资本19631.2325万 人民币。公司法定代表人为金海荣。 通过天眼查大数据分析，熵基科技股份有限公司共对外投资了16家企业，参与招投标项目1424次，知识 产权方面有商标信息928条，专利信息1172条，此外企业还拥有行政许可21个。 来源：金融界 金融界消息 截至2025年7月31日收盘，熵基科技（301330）报收于29.21元，上涨3.8%，换手率 18.84%，成交量17.27万手，成交金额4.95亿元。 资金流向方面，今日主力资金净流入6031.32万元，占比成交额12.2%。其中，超大单净流入3336.02万 元、占成交额6.75%，大单净流入2695.29万元、占成交额5.45%，中单净流出流出432.52万元、占成交 额0.87%，小单净流出5598.80万元、占成交额11.32%。 熵基科技最新一期业绩显示，截至2025一季报，公司营业总收入4.14亿元、同比增长3.50%，归属净利 润2946.27万元，同比增 ...

7月31日，人脑工程概念上涨0.27%，今日主力资金流入7729.22万元，概念股14只上涨，19只下跌。 主力资金净流入居前的分别为科大讯飞（2.28亿元）、创新医疗（9399.58万元）、乐普医疗（6230.96 万元）、熵基科技（6031.32万元）、爱朋医疗（3162.54万元）。 来源：金融界 序号代码名称最新价涨跌幅主力净流入主力净占比1002230科大讯飞48.780.762.28亿元8.28%2002173创 新医疗15.347.729399.58万元8.27%3300003乐普医疗15.560.846230.96万元5.49%4301330熵基科技 29.213.86031.32万元12.2%5300753爱朋医疗31.397.283162.54万元5.27%6002195岩山科技5.741.232957.49 万元1.87%7301293三博脑科50.083.582790.86万元3.88%8603610麒盛科技12.662.592028.90万元 9.16%9300678中科信息33.980.651515.56万元3.66%10688273麦澜德33.76-0.591193.99万元9. ...

Core Viewpoint - The news highlights a significant rise in brain-computer interface (BCI) concept stocks, driven by new pricing mechanisms introduced by the National Healthcare Security Administration (NHSA) to support innovation in pharmaceuticals and medical devices [1] Group 1: Market Reaction - BCI-related stocks such as Innovation Medical are nearing their daily limit up, with other companies like Aipeng Medical, Sanbo Brain Science, Entropy Technology, Qisheng Technology, and Yanshan Technology also experiencing gains [1] Group 2: Policy Changes - The NHSA has established a new pricing mechanism for newly launched drugs, adding over 100 pricing items related to new medical technologies [1] - Specific pricing items for the nervous system have been introduced, including "BCI implantation fees" and "BCI adaptation fees," which will facilitate rapid clinical application and charging once BCI technology is approved for clinical use [1] - Guidelines for ear, nose, and throat (ENT) procedures now include pricing for "cochlear implant fees" and "speech device installation fees," encouraging medical institutions to assist more patients in communication [1] - Pricing items for radiation therapy have been standardized, including "proton therapy" and "heavy ion therapy," promoting the clinical application of advanced medical equipment [1]

消息面上，为支持药品和医疗器械创新发展，国家医保局制定新上市药品首发价格机制，新增了100多 项与医疗新技术相关的价格项目。神经系统类立项指南统一设立"脑机接口置入费""脑机接口适配费"等 价格项目，脑机接口技术成熟获批进入临床后，可快速进入临床应用并收费。耳鼻喉类立项指南统一设 立"人工耳蜗植入费""发音装置安装费"等价格项目，鼓励医疗机构帮助更多患者"听得见、说得出"。放 射治疗类立项指南统一设立"质子放疗""重离子放疗"等价格项目，促进高端医疗设备的临床转化应用。 与此同时，为鼓励药品研发创新，国家医保局还制定了新上市药品首发价格机制。 格隆汇7月31日｜脑机接口概念股拉升，其中，创新医疗逼近涨停，爱朋医疗、三博脑科、熵基科技、 麒盛科技、岩山科技等跟涨。 ...

证券代码：301330 证券简称：熵基科技 公告编号：2025-067 熵基科技股份有限公司 关于注销及开立闲置募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 为提高闲置募集资金使用效率，合理利用暂时闲置的募集资金，增加公司投 资收益和股东回报，熵基科技股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开第三届董事会第十一次会议和第三届监事会第十次会议，审议通过 了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司及子公司 使用不超过人民币 80,000 万元（含本数）的部分暂时闲置募集资金（含超募资 金）进行现金管理，该使用额度及授权的有效期自公司董事会审议通过之日起 12 个月内有效，并在上述额度内滚动使用。具体内容详见公司于 2024 年 8 月 30 日 在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于使用部分暂时闲置募集 资金进行现金管理的公告》（公告编号：2024-040）。 一、注销闲置募集资金现金管理专用结算账户的情况 因购买理财产品的需要，公司在招商银 ...

Group 1 - The unmanned retail concept declined by 1.34%, ranking among the top declines in the concept sector, with notable declines in companies like Huijin Co., Shanjike Technology, and Shen Si Electronics [1][2] - Among the unmanned retail sector, 24 stocks experienced net outflows of main funds totaling 319 million yuan, with Huijin Co. leading the outflow at 168 million yuan [2][3] - The top gainers in the unmanned retail sector included Gongxiao Daji, Xinbeiyang, and Hongqi Lianchuan, with increases of 2.59%, 1.92%, and 1.28% respectively [1][2] Group 2 - The main funds saw a net inflow in stocks like Gongxiao Daji and Xin Kaipu, with inflows of 126 million yuan and 16.43 million yuan respectively [2][3] - The top stocks with significant net outflows included Huijin Co. (-17.70%), Kela Software (-2.48%), and Newland (-0.15%) [2][3] - The overall market sentiment reflected a mixed performance across various concept sectors, with silicon energy leading gains at 3.39% while the unmanned retail sector faced notable declines [2]

Group 1 - *ST San Sheng (002742.SZ): The controlling shareholder Pan Xianwen's 32.2 million shares have been transferred, accounting for 7.30% of the total share capital, reducing his holding from 17.26% to 16.75, with no change in company control [1] - Aikang Co., Ltd. (300889.SZ): Shareholders Zhang Fengbin and Feng Renrong reduced their holdings by a total of 1.76 million shares, accounting for 1.06% of the total share capital, completing the reduction plan [1] - Allianz Ruishi (301042.SZ): Director Shen Lei reduced his holdings by 98,700 shares, accounting for 0.14% of the total share capital, with the reduction plan period ending [1] Group 2 - Baotong Technology (300031.SZ): Controlling shareholder Bao Zhifang and director Tang Yu plan to reduce their holdings by up to 8.3749 million shares and 1.526988 million shares, accounting for no more than 2% and 0.36% of the total share capital, respectively [2] - Biyiwei (688045.SH): Shareholders Fang Guang Erqi and Yuan Chengjun plan to reduce their holdings by up to 139,680 shares and 69,840 shares, accounting for no more than 2% and 1% of the total share capital, respectively [2] - Chahua Co., Ltd. (603615.SH): Shareholder Shenzhen Hanjinliang reduced 2.397 million shares, accounting for 0.99% of the total share capital, completing the reduction plan [2] Group 3 - Dacai Co., Ltd. (605287.SH): Shareholder Qingdao Dikuang Chanquan Development Co., Ltd. reduced 3.64 million shares, accounting for 2.60% of the total share capital, completing the reduction plan [3] - Dize Pharmaceutical (688192.SH): Vice President Zhang Shiying reduced 161,550 shares, accounting for 0.0035% of the total share capital, completing the reduction plan [3] - Fuhan Micro (300613.SZ): Controlling shareholder's concerted action party plans to reduce up to 6.90208 million shares, accounting for 3% of the total share capital [3] Group 4 - Guanghuan Xinwang (300383.SZ): Directors and vice presidents plan to reduce a total of up to 720,476 shares, accounting for no more than 0.04% of the total share capital [4] - Hanyu Group (300403.SZ): Director and Vice President Wu Geming plans to reduce up to 1 million shares, accounting for 0.1658% of the total share capital [4] - Haosen Intelligent (688529.SH): Shareholders plan to reduce a total of up to 3 million shares, accounting for 1.7838% of the total share capital [4] Group 5 - Huilong New Materials (301057.SZ): Controlling shareholder's concerted action party plans to reduce up to 3.482902 million shares, accounting for 3% of the total share capital excluding repurchased shares [5] - Huitong Co., Ltd. (688219.SH): Shareholder Tong'an Fund reduced 4.667815 million shares, accounting for 0.93% of the total share capital, completing the reduction plan [5] Group 6 - Jiangsu Shentong (002438.SZ): Shareholder Huzhou Fenglin Huoshan Equity Investment Partnership reduced a total of 14.205 million shares, accounting for 2.798808% of the total share capital, completing the reduction plan [6] - Jiangtian Chemical (300927.SZ): Shareholder Jiangshan Co., Ltd. reduced 1.3265 million shares, accounting for 0.92% of the total share capital [6] - Jin Sanjiang (301059.SZ): Shareholder Guangzhou Saina reduced 104,900 shares, accounting for 0.05% of the total share capital, completing the reduction plan [6] Group 7 - Jingxue Energy (301010.SZ): Controlling shareholder's concerted action party reduced 1.08 million shares, accounting for 1% of the total share capital, completing the reduction plan [7] - Jiuwu High-Tech (300631.SZ): Vice President Wang Xiaohu and Cheng Junjun plan to reduce up to 18,900 shares and 5,000 shares, accounting for no more than 0.1511% and 0.04% of the total share capital, respectively [7] - Kanghui Pharmaceutical (603139.SH): Shareholder Shanghai Sailoxian plans to reduce up to 2.9964 million shares, accounting for 3% of the total share capital [7] Group 8 - Meino Biological (301156.SZ): Shareholder's concerted action party reduced 1.297029 million shares, accounting for 0.92% of the total share capital, completing the reduction plan [8] - Minfa Aluminum Industry (002578.SZ): Shareholder Huang Tianhuo reduced 6.6702 million shares, accounting for 0.71% of the total share capital, reducing his holding to 4.9963% [8] - Nuo Puxin (002215.SZ): Directors and senior management plan to reduce a total of up to 1.8607 million shares, accounting for no more than 0.185% of the total share capital [8] Group 9 - Entropy Technology (301330.SZ): Shareholders reduced a total of 4,693,864 shares, accounting for 1.9556% of the total share capital, completing the reduction plan [9] - Shengbang Co., Ltd. (301233.SZ): Supervisor Hu Jilin plans to reduce up to 5,650 shares, accounting for 0.0111% of the total share capital [9] - Shudao Equipment (300540.SZ): Senior management did not reduce their shares, and the reduction plan period has ended [9] Group 10 - Tongyu Communications (002792.SZ): Controlling shareholder and actual controller Shi Guiqing plans to reduce up to 15,653,487 shares, accounting for 2.9963% of the total share capital [10] Group 11 - Wuzhou Xinchun (603667.SH): Senior management plans to reduce a total of up to 22,500 shares, accounting for no more than 0.0061%, 0.0067%, and 0.0037% of the total share capital [11] - New Sharp Co., Ltd. (688257.SH): Senior management plans to reduce up to 750,000 shares, accounting for no more than 0.2971% of the total share capital [11] - New Hope (000876.SZ): Senior management reduced 225,000 shares, accounting for 0.005% of the total share capital, completing the reduction plan [11] Group 12 - Youke De (688158.SH): Shareholder Zhongyi Capital reduced 882,766 shares, accounting for 0.19% of the total share capital, completing the reduction plan [12] - Changqing Technology (001324.SZ): Shareholders reduced a total of 4,165,050 shares, accounting for 3.00% of the total share capital, completing the reduction plan [12] - Changxin Bochuang (300548.SZ): Shareholders plan to reduce up to 8.6 million shares, accounting for 2.95% of the total share capital [12] Group 13 - Zhongfu Industrial (600595.SH): Shareholder Henan Yicheng Chuangtou plans to reduce up to 40 million shares, accounting for 1% of the total share capital [13] - Zhuhai Ming Technology (300232.SZ): Controlling shareholder Lin Mingfeng plans to reduce up to 21,722,009 shares, accounting for 1.99% of the total share capital [13] - Zhuoyi Information (688258.SH): Employee shareholding platform plans to reduce up to 2,271,445 shares, accounting for no more than 1.88% of the total share capital [13]

证券代码：301330 证券简称：熵基科技 公告编号：2025-066 熵基科技股份有限公司 关于持股 5%以上股东减持计划期限届满的公告 股东深圳精英士君投资企业（有限合伙）及深圳精英和义投资企 业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 熵基科技股份有限公司（以下简称"公司"或"熵基科技"）于 2025 年 3 月 17 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东减持股 份计划预披露公告》，公司持股 5%以上的股东深圳精英士君投资企业（有限合 伙）（以下简称"精英士君"）及深圳精英和义投资企业（有限合伙）（以下简 称"精英和义"）计划自减持计划预披露公告之日起十五个交易日后的三个月内， 分别以集中竞价和/或大宗交易方式减持公司股份不超过 2,886,600 股（不超过公 司剔除回购专用账户中股份数量后总股本的 1.4873%）。本次减持计划实施前， 精英士君持有公司股份 14,038,400 股，占公司总股本的 7.1511%；精英和义持有 公 ...

证券代码：301330 证券简称：熵基科技 公告编号：2025-065 熵基科技股份有限公司 关于开立闲置募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 为提高闲置募集资金使用效率，合理利用暂时闲置的募集资金，增加公司投 资收益和股东回报，熵基科技股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开第三届董事会第十一次会议和第三届监事会第十次会议，审议通过 了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司及子公司 使用不超过人民币 80,000 万元（含本数）的部分暂时闲置募集资金（含超募资 金）进行现金管理，该使用额度及授权的有效期自公司董事会审议通过之日起 12 个月内有效，并在上述额度内滚动使用。具体内容详见公司于 2024 年 8 月 30 日 在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于使用部分暂时闲置募集 资金进行现金管理的公告》（公告编号：2024-040）。 一、开立闲置募集资金现金管理专用结算账户的情况 近日，公司新开立了闲置募集资金现金管理专 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by advancements from companies like Neuralink and recent breakthroughs in China, indicating a potential commercialization of BCI technology in the near future [2][4][5]. Group 1: Neuralink Developments - Neuralink has showcased its latest research and product development, with 7 participants currently using the device for an average of 50 hours per week, peaking over 100 hours [2]. - The company plans to implant devices in the speech cortex by the end of 2025 to decode silent speech from brain signals, and aims to increase electrode channels to 3,000 by 2026 to explore restoring vision [2][3]. - By 2028, Neuralink anticipates implanting over 25,000 electrodes to address mental health issues and explore integration with AI, potentially allowing humans to control robots directly [3]. Group 2: Market Potential and Growth - The global BCI market is projected to grow from $2.62 billion in 2024 to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% [4]. - The BCI technology is recognized as one of the most disruptive technologies of the 21st century, with expectations for a surge in medical product applications over the next 5 to 10 years [4]. Group 3: Domestic Developments in China - Recent successful trials in China, including the first invasive BCI-assisted rehabilitation for a stroke patient, highlight the rapid advancement of BCI technology towards commercialization [4]. - The "Beijing Brain Institute" has developed a flexible, high-throughput, semi-invasive BCI system that has entered clinical trials, marking significant progress in the field [4]. Group 4: Industry Insights - The domestic BCI industry is benefiting from technological breakthroughs and supportive government policies, which are expected to accelerate the commercialization process [5]. - BCI products are categorized into non-invasive and invasive types, with non-invasive products leading in commercialization, while invasive products are still in clinical research stages [6]. - Despite the promising outlook, the BCI industry faces challenges related to safety, regulatory approval, and the need for foundational research [6][7].